Food and Drug Administration
recently expanded the approved use of Zytiga (abiraterone acetate) to treat men
with late-stage (metastatic) castration-resistant prostate cancer prior to
receiving chemotherapy. The FDA initially approved the drug in April 2011 for
use in patients whose prostate cancer progressed after treatment with
docetaxel, a chemotherapy drug. U.S.
In prostate cancer, testosterone stimulates prostate tumors to grow. Drugs or surgery are used to reduce male sex hormone testosterone production or to block testosterone’s effects. Zytiga decreases the production of testosterone. Some men have castration-resistant prostate cancer, meaning the prostate cancer cells continue to grow even with low levels of testosterone.